[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Institut Pasteur\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":601},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,34,0,25,[9,39,63,85,111,136,165,190,217,240,261,283,307,335,361,381,406,429,448,474,496,520,543,564,584],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100645136","optimization-of-perceived-sound-quality-for-music-listening-in-hearing-aid-users-with-hearing-loss-100645136",false,"NCT07677748","Optimization of Perceived Sound Quality for Music Listening in Hearing Aid Users With Hearing Loss.","OPTIMisation de la qualité Sonore perçue Pour l'écoute de la MUSIque Chez Les Malentendants appareillés","OPTIMMUSIC","Inclusion Criteria:\n\nFor all participants:\n\n* Aged 18 years or older,\n* Fitted with hearing aids for at least 6 months,\n* Reporting dissatisfaction with music listening while using their hearing aids.\n\nFor musician participants:\n\n• Defined as instrumentalists or knowledgeable music enthusiasts engaging in daily music practice for a minimum of 4 hours.\n\nFor non-musician participants:\n\n• Defined as individuals without formal musical training who listen to music for at least one hour per day\n\nExclusion Criteria:\n\n* Asymmetric hearing loss (pure-tone audiometry showing a difference between the two ears \\> 15 dB)\n* Irregular use of hearing aids: \\\u003C 4 hours per day","ALL","18 Years",{"count":21,"type":22},66,"ESTIMATED","OBSERVATIONAL","This study aims to optimize music listening quality for 66 hearing aid users (33 musicians and 33 non-musician music enthusiasts) by developing a dedicated \"Music Program\" based on individual frequency preference profiles. We will evaluate the program's efficacy by comparing listening quality and emotional response scores against standard settings, while also investigating correlations with music reward sensitivity. We hypothesize that the customized program will yield significant improvements, with a more pronounced benefit observed in the musician group.",[26],"Hearing Impaired (Partially)","NOT_YET_RECRUITING","2026-06-25",{"date":30,"type":31},"2026-07-01","ACTUAL",{"date":33,"type":22},"2026-09",{"date":35,"type":22},"2028-05",{"name":37,"class":38},"Institut Pasteur","INDUSTRY",{"id":40,"slug":41,"hasResults":12,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":48,"conditions":49,"keywords":52,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":60,"leadSponsor":62,"locationsCount":4},"100640589","ex-vivo-study-of-leukocyte-responses-in-the-blood-of-patients-with-leptospirosis-and-ex-vivo-testing-of-a-new-host-targeted-therapeutic-strategy-to-restore-phagocytosis-of-leptospira-100640589","NCT07611591","Ex Vivo Study of Leukocyte Responses in the Blood of Patients With Leptospirosis and ex Vivo Testing of a New Host-targeted Therapeutic Strategy to Restore Phagocytosis of Leptospira","NEUTROLEPTO-NC","Inclusion Criteria:\n\n* Be of legal age (18 years or older at the time of enrollment),\n* Be capable of understanding and providing informed consent,\n* Have received information and provided written consent,\n* Be enrolled in a social security program.\n* Be suspected of having leptospirosis\n\nExclusion Criteria:\n\n* With a chronic inflammatory disease,\n* Whose health condition is incompatible with additional blood draws totaling 40 ml,\n* Receiving concomitant treatment with antibiotics and\u002For anti-inflammatory drugs, or undergoing medical treatment incompatible with the study's objectives,\n* Pregnant or breastfeeding women.\n* Hospitalized or having undergone surgery within the previous 7 days",{"count":47,"type":22},70,"Leptospirosis is a neglected zoonosis caused by pathogenic spirochetes of the genus \\*Leptospira\\*, occurring mainly in humid tropical and subtropical regions. With over one million cases and \\~60,000 deaths annually, it is among the most dangerous bacterial zoonoses worldwide. Its nonspecific onset-fever, headache, myalgia-mimics influenza, dengue, and other acute febrile illnesses, making diagnosis difficult. Delayed antibiotic treatment can lead to severe forms (in \\~10% of cases) characterized by hemorrhage and multi-organ failure. In 2023, New Caledonia reported 152 cases, with 85% hospitalized and a 2.6% mortality rate.\n\nThis study aims to characterize the human host response and improve patient management. \\*Leptospira\\* evades innate immunity, triggering a strong anti-inflammatory IL-10 response and potentially ineffective phagocytosis. However, the WHO-recommended β-lactam antibiotics induce a Jarisch-Herxheimer reaction (JHR)-an acute inflammatory response occurring within hours of treatment-in over 50% of patients (LEPJAR study, PMID:40986630), the impact of which on phagocytosis is unknown.The NEUTROLEPTO study will be conducted in New Caledonia (NC) in patients with or without leptospirosis. Clinical and biological data will be collected at the time of suspected infection and 3 hours after antibiotic administration. Specifically, immune responses will be assessed through cytokine profiling and blood cell phenotyping, as well as by transcriptome analysis of infected patients before and after antibiotic treatment.",[50,51],"Leptospirosis","Jarisch Herxheimer Reaction",[53,51,54,55],"leptospirosis","Inflammation","ß-lactams antibiotics","2026-05-21",{"date":58,"type":31},"2026-05-28",{"date":30,"type":22},{"date":61,"type":22},"2029-07-01",{"name":37,"class":38},{"id":64,"slug":65,"hasResults":12,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":83,"locationsCount":84},"100595146","effectiveness-of-speech-therapy-for-lip-reading-in-patients-with-hearing-aids-sced-study-100595146","NCT07028658","Effectiveness of Speech Therapy for Lip-reading in Patients With Hearing Aids: SCED Study","Efficacité de la rééducation Orthophonique de la Lecture Labiale Des Patients appareillés Auditifs : étude SCED","SCEDuLL","Inclusion Criteria:\n\n* Patient aged 18 or older\n* Affiliated with a social security system\n* Moderate to severe bilateral post-lingual hearing loss, fitted with hearing aids for more than 6 months\n* Wearing hearing aids for a minimum of 8 hours\u002Fday on average over the past month\n* Intelligibility in quiet \\> 80% correct responses at 60 dB (Lafon cochlear list)\n* Difficulty in noisy environments rated \\> 6 on a 0-10 EVA scale\n* French language comprehension level of at least B1 CEFR (Common European Framework of Reference for Languages)\n* Willing to participate in speech therapy rehabilitation at a rate of 2 sessions per week\n\nExclusion Criteria:\n\n* Patient who has already undergone speech therapy rehabilitation as part of their hearing loss treatment\n* Diagnosis of neurodegenerative disease or history of brain injury (traumatic brain injury, stroke, tumor, meningitis, etc.)\n* Uncorrected vision or visual impairment affecting lip reading (e.g. AMD, glaucoma, unoperated cataract, etc.)\n* Presence of severe tinnitus (score \\> 56) on the Tinnitus Handicap Inventory (THI) questionnaire\n* Significant cognitive impairment (CODEX C or D) or Montreal Cognitive Assessment (MOCA) score \\\u003C 23",{"count":72,"type":22},8,"This study aims to investigate whether lip reading rehabilitation improves viseme recognition in individuals with hearing impairments who use hearing aids.",[75],"Hearing Loss, Bilateral or Unilateral","RECRUITING","2026-03-30",{"date":79,"type":31},"2026-04-03",{"date":81,"type":31},"2025-10-16",{"date":33,"type":22},{"name":37,"class":38},1,{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":93,"sex":18,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":84},"100569195","sound-perception-study-of-hearing-impaired-people-with-hearing-aids-100569195","NCT06691087","Sound Perception Study of Hearing-impaired People With Hearing Aids","ÉTude de la pERception soNorE de Personnes maLentendantes équipées d'Aides Auditives","ETERNEL","Inclusion Criteria:\n\nFor all participants:\n\n* Age between 60 and 75\n* Native French speaker\n* Have given their consent to take part in the study.\n* Declare that they have an active social life or hobbies that stimulate their cognitive abilities\n* Have a MOCA score above 26\n* No tympano-ossicular dysfunction.\n* Voice in noise audiometry results showing normal results.\n\nFor participants with impaired hearing :\n\n* Pure tone audiometry showing audiograms of type N3 or N4 and symmetrical between the two ears.\n* Report having experienced problems with abnormally prominent sound.\n\nFor participants with normal hearing:\n\n\\- Pure tone audiometry showing audiograms with losses of less than 30 dBHl.\n\nExclusion Criteria:\n\n* Be under guardianship or curatorship,\n* Be deprived of liberty by judicial or administrative decision, or be under legal protection.\n* Bear the consequences of an ear infection and\u002For have a history of an ENT disease that permanently affects hearing or balance (vestibular schwannoma, Ménière's disease, sudden or fluctuating deafness, congenital hypoacusis).",true,"60 Years","75 Years",{"count":97,"type":22},75,"INTERVENTIONAL",[100],"NA","The aim of the ETERNEL project will be to study the influence of the perception of a single sound timbre on the understanding of a complex sound scene in hearing-impaired people with hearing aids. This will be done by quantifying the inability to manage a complex sound scene as a function of the timbre of the sounds making it up. The more a sound interferes with understanding the complex sound scene, the more salient that sound is considered to be. In this way, the investigators can determine which timbre dimensions make sounds particularly salient for the hearing impaired.",[103],"Auditory Perception",{"date":105,"type":31},"2026-03-31",{"date":107,"type":31},"2025-04-22",{"date":109,"type":22},"2028-11",{"name":37,"class":38},{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":93,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":120,"conditions":121,"keywords":124,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100608773","gut-microbiota-diet-induced-obesity-and-type-2-diabetes-in-new-caledonia---mind-100608773","NCT07205913","Gut Microbiota, Diet-INDuced Obesity and Type 2 Diabetes in New Caledonia - MIND","MIND","Inclusion Criteria:\n\n* Aged between 18 and 60 years.\n* Ability to understand and provide informed consent.\n* Ability and willingness to meet the required schedule and study interventions.\n* Willingness to share their community belonging\n* Benefit from a social security system.\n\nFor obese and diabetic patients :\n\n* IMC ≥ 30 kg\u002Fm² with type 2 diabetes\n* Fasting plasma glucose (FPG) ≥7 mM (=1.26g\u002Fl) or\n* Patients with HbA1c ≥ 6.5% (48 mmol\u002Fmol)\n* All stages of albuminuria For obese patients without type 2 diabetes\n* IMC ≥ 30 kg\u002Fm²\n* Weight stable for at least 2 months\n* Patients with normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and\u002For impaired fasting glucose (IFG) and an HbA1c \\\u003C 6.5 %\n* No treatment (diabetic or weight loss)\n* Match age (±5years), sex and self-reported community to the patients from the1 group.\n\nFor control group :\n\n* BMI between 18.5-24.9 kg\u002Fm²\n* Match age (±5years), sex and self-reported community to the patients from the 1 and 2 groups.\n* Participants with normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and\u002For impaired fasting glucose (IFG) and an HbA1c \\\u003C 6.5 %\n\nExclusion Criteria:\n\nAll participants :\n\n* Treatment that may alter gastrointestinal motor function, acidity, microbial population, or immunosuppressants\n* Altered anatomy of the esophagus, stomach, small intestine, or large intestine due to gastrointestinal surgery (except appendectomy or cholecystectomy)\n* Chronic or acute inflammatory bowel disease or infections\n* Abdominal or pelvic radiation therapy or abdominal cancer, colorectal cancer\n* Dysphagia, eosinophilic esophagitis, esophageal stricture, or other swallowing disorders\n* Organ transplantation and patients receiving immunosuppressive therapy\n* Severe renal failure and\u002For patients undergoing dialysis\n* Cardiovascular, endocrine, renal, or other chronic disease that may affect motility.\n* Preparation for colon cleansing within the last month\n* \\\u003C 3 bowel movements per week\n* Women who are pregnant or breastfeeding",{"count":119,"type":22},270,"In recent years, the global rise in obesity and type 2 diabetes has become a major public health issue. In New Caledonia, 38% of the adult population has a body mass index ≥30. At the same time, the prevalence of type 2 diabetes continues to rise steadily. The burden of these diseases does not affect communities uniformly. While known factors such as diet, physical activity, and socioeconomic conditions play a role, studies have demonstrated the involvement of the gut microbiota in the development of metabolic disorders, particularly obesity and insulin resistance. However, this area remains largely unexplored in New Caledonia and the Pacific.",[122,123],"Diabetes Mellitus, Type 2","Obesity",[125,126,127],"microbiota","New Caledonia","metabolic diseases","2026-03-06",{"date":130,"type":31},"2026-03-09",{"date":132,"type":22},"2026-02-15",{"date":134,"type":22},"2027-02-15",{"name":37,"class":38},{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":93,"sex":18,"minAge":19,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":4},"100615329","impact-of-sex-hormones-on-human-skin-immunity-in-health-and-hidradenitis-suppurativa-siap-100615329","NCT07291193","Impact of Sex Hormones on Human Skin Immunity in Health and Hidradenitis Suppurativa (SIAP)","Impact of Sex Hormones on Human Skin Immunity in Health and Hidradenitis Suppurativa","SIAP","Inclusion Criteria:\n\n* Common criteria :\n* Subject\\>18 years and \\\u003C45 years,\n* Written informed consent of the subject,\n* Subject affiliated to the Assurance Maladie (French Health System) except Aide Médicale d'Etat (French State Medical Aid),\n* Subject agrees that genomic analyses may be carried out on the samples\n* Specific criteria :\n* For pregnant women:Third trimester of pregnancy (between 29-37 weeks of amenorrhea).\n* For HS subjects: Subject with hidradenitis suppurativa lesions at the sampling sites.\n\nExclusion Criteria:\n\n* Common criteria :\n* Subject immunocompromised,\n* Subject under legal protection (guardianship or curatorship),\n* Subject is unable to provide informed consent and to comply with the study requirements due to geographical, social, or psychiatric reasons,\n* Subject in other research whose procedures may influence the immune system,\n* Contraindication to any of medications listed in section 5.1 (antiseptic and local anesthetic used for biopsy(ies)),\n* Subject whose health condition does not permit participation in study procedures.\n* Specific criteria :\n* For no HS subjects : Scarred skin at the biopsy site, Subject with pre-existing and\u002For still active inflammatory skin conditions, Subject experiencing early menopause (women) or andropause (men).","45 Years",{"count":146,"type":22},240,"Sex hormones are major regulators of skin immunity. Pregnancy represents a unique physiological state of profound hormonal remodeling. In late pregnancy, maternal levels of estrogens, progesterone, and other hormones increase dramatically, offering an unparalleled model to study the impact of sex hormones on skin immunity. Hidradenitis suppurativa (HS) provides a clinically relevant model to examine how sex hormones modulate skin inflammation.",[149],"Skin Immunity",[151,152,153,154,155,156],"Pregnancy","Maternal Immunity","Skin","Hormones","Single Cell","Spatial-Omics","2026-01-08",{"date":159,"type":31},"2026-01-09",{"date":161,"type":22},"2026-01",{"date":163,"type":22},"2031-03",{"name":37,"class":38},{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":18,"minAge":173,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":98,"phases":177,"briefSummary":178,"conditions":179,"keywords":181,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":187,"leadSponsor":189,"locationsCount":4},"100616269","a-rhythmic-and-auditory-approach-for-children-with-autism-spectrum-disorders-asd-100616269","NCT07303413","A Rhythmic and Auditory Approach for Children With Autism Spectrum Disorders (ASD)","Approche Rythmique et Auditive Chez Les Enfants Avec Troubles du Spectre de l'Autisme (TSA)","THETABOOST","Inclusion Criteria:\n\n* aged between 3 and 6 at the time of inclusion\n* Have received a formal medical diagnosis of ASD\n* Have the consent of the parent(s)\n* Declaration of a language delay by the parents\n* Affiliated to social security or equivalent scheme\n\nExclusion Criteria:\n\n* Conditions likely to interfere with the EEG and make its interpretation difficult, including severe epilepsy or cerebral malformations.\n* Treatments likely to interfere with the EEG (sedatives, psychostimulants, anxiolytics, antidepressants).\n* Known hearing impairment","3 Years","6 Years",{"count":176,"type":22},24,[100],"The aim of this study is to assess the effectiveness of a rhythmic auditory training program in improving language skills in children with Autism Spectrum Disorder (ASD) who have a language acquisition disorder. The program focuses on training children to reproduce the syllable rhythms of speech, and the study will evaluate the children's language skills before and after participating in the program.",[180],"Autism Spectrum Disorder",[182],"language","2025-12-18",{"date":185,"type":31},"2025-12-24",{"date":161,"type":22},{"date":188,"type":22},"2027-09",{"name":37,"class":38},{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":98,"phases":200,"briefSummary":201,"conditions":202,"keywords":204,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":84},"100600437","virus-transmission-to-people-recently-bitten-or-with-a-history-of-monkey-bites-simvir-100600437","NCT07097480","Virus Transmission to People Recently Bitten or With a History of Monkey Bites \"SIMVIR","Virus Transmission to People Recently Bitten or With a History of Monkey Bites \"SIMVIR\"","SIMVIR","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Bite inflicted by an HNP (WHO category 3 level)\n* Written informed consent\n* Affiliation with a social security scheme (excluding State Medical Aid\n\nSpecific criteria for genetic analyses:\n\n* Participant has checked the boxes for participation in the genetic component.\n\nExclusion Criteria:\n\n* Patient presenting only with scratches inflicted by a PNH\n* Medical management incompatible with the objectives of the study\n* Patient who, in the doctor's opinion, is unlikely to comply with the study protocol\n* Health conditions are incompatible with the sample collection required by the study\n* Patient under legal protection (guardianship or trusteeship)",{"count":199,"type":22},80,[100],"Nonhuman primates (NHPs) constitute an important reservoir of infectious agents, some of which have emerged in human populations as deadly pathogens. Human exposure to the biological fluids of NHPs - particularly through bites - can result in the transmission of several viruses. Only the rabies virus is currently targeted by post-exposure prophylaxis following an injury caused by an NHP.\n\nThe objective of the study is to investigate the prevalence of STLV-1 and SFV infections following a nonhuman primate bite.",[203],"Bites Monkey",[205,206,207,208],"Antirabies","Virus","Bite","Infection","2025-12-08",{"date":211,"type":31},"2025-12-15",{"date":213,"type":31},"2025-08-14",{"date":215,"type":22},"2028-08",{"name":37,"class":38},{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":93,"sex":224,"minAge":19,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":226,"conditions":227,"keywords":229,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":234,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":84},"100572845","impact-of-breast-milk-on-the-infectivity-and-transmission-of-different-viruses-breastmilkvir-100572845","NCT06738563","Impact of Breast Milk on the Infectivity and Transmission of Different Viruses \"BREASTMILKVIR\"","BREASTMILKVIR","Inclusion Criteria:\n\n* Age \\> 18 years\n* Female gender\n* Lactarium Ile-de-France donors\n* Subjects covered by a Social Security scheme, excluding State Medical Aid\n\nNo inclusion criteria:\n\n\\- Women opposing participation in the study\n\nExclusion Criteria:\n\n\\- Positive HIV, HBV, HCV and HTLV serologies (Lactarium exclusion criteria)","FEMALE",{"count":97,"type":22},"Exclusive breastfeeding during the first six months of life and continued breastfeeding for at least 24 months constitute the optimal feeding method for infants and young children.\n\nHowever, breast milk and breastfeeding can be significant pathways for the transmission of certain viruses.\n\nThe objective of this study is to examine the influence of human breast milk and its composition on viral infectivity and viral transmission of the HTLV-1 virus and arboviruses such as Zika virus, yellow fever, dengue, and tick-borne encephalitis.",[228],"Breastmilk Collection",[230,231,206,232,233],"Milk","Maternal","Transmission","Infectivity",{"date":211,"type":31},{"date":236,"type":31},"2025-09-10",{"date":238,"type":22},"2030-09",{"name":37,"class":38},{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":93,"sex":224,"minAge":19,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":98,"phases":249,"briefSummary":250,"conditions":251,"keywords":253,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":84},"100569478","vac-sip-yf-vaccination--safety--immunogenicity-during-pregnancy--yellow-fever-100569478","NCT06694766","VAC-SIP-YF (Vaccination- Safety & Immunogenicity During Pregnancy- Yellow Fever)","Comparative Study of Tolerance and Immunogenicity Induced by Primary Yellow Fever Vaccination in Pregnant and Non-pregnant Women","VAC-SIP-YF","Inclusion Criteria:\n\nCommon :\n\n* Person over 18 years of age at the time of the first yellow fever vaccination\n* Female gender\n* Oral consent obtained after subject has been informed\n* Subject covered by Social Security with the exception of Aide Médicale d'Etat\n\nSpecific to both groups :\n\n* For women vaccinated during pregnancy (case): Primary yellow fever vaccination during pregnancy\n* For women vaccinated outside pregnancy (control): Primary yellow fever vaccination outside pregnancy\n\nExclusion Criteria:\n\nCriteria common to both sections (tolerance and immunogenicity):\n\n* Subject having received a second yellow fever vaccination\n* Persons unable to give informed consent for participation\n* Women born in areas where yellow fever is endemic\n* Female adults under legal protection (guardianship or trusteeship)\n\nSpecific criteria for participants in the immunogenicity section:\n\n* Medical condition imcompatible with 18.5 mL blood\n* Women who have not given written consent to participate in the study. immunogenicity",{"count":119,"type":22},[100],"The aim of this study is to compare the immunogenicity induced by yellow fever vaccination administered during pregnancy with that induced by vaccination outside pregnancy, and to assess the maternal and fetal tolerance of this vaccination.",[252],"Yellow Fever Vaccine",[254],"Yellow Fever Vaccination Tolerance Immunogenicity Pregnancy",{"date":211,"type":31},{"date":257,"type":31},"2025-03-24",{"date":259,"type":22},"2030-03",{"name":37,"class":38},{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":93,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":98,"phases":271,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":84},"100313213","genetic-susceptibility-to-listeriosis-100313213","NCT03357536","Genetic Susceptibility to Listeriosis","Genetic Susceptibility to Listeriosis - Listeria-GEN","Listeria-GEN","Inclusion Criteria for patients with Listeriosis :\n\n* Microbiologically documented Listeriosis (either a severe form of listeriosis, or an atypical form of listeriosis, or less than 40 years old and without any co-morbidity identified)\n* Affiliated or beneficiary of a social security system\n* Informed and written consent\n\nInclusion Criteria for volunteers related to patients with Listeriosis (after identifying a genetic susceptibility in the patient with Listeriosis) :\n\n* defined as father, mother, brother (s), sister (s), child (ren), grandparent (s), uncle (s), aunt (s), cousin (s), nephew (s), niece (s).\n* Affiliated or beneficiary of a social security system\n* Informed and written consent\n\nExclusion Criteria for volunteers related to patients with Listeriosis:\n\n* Inability to consent",{"count":270,"type":22},100,[100],"Listeriosis is a rare, severe foodborne infection, responsible for severe invasive infections. It occurs in the great majority of cases in elderly patients and \u002F or patients with comorbidities, with a deficit of innate or cellular immunity. Pregnancy is also a risk factor.\n\nThe Multicentric Observational NAtional Analysis of Listeriosis and Listeria (MONALISA) is an ongoing national case-control prospective study on listeriosis implemented since 2009 to study risk and prognosis factors for listeriosis. In this cohort, which enrolled 902 patients on 1 August 2014, 7% of patients with neurolisteriosis are under 40 years of age and have no identified risk factor. Genetic susceptibility is suspected in these patients. Genetic susceptibility could also explain the inconstant development of a neurolisteriosis or fetal infection, as well as the particular severity of some infections (death, foetal loss, neurological sequelae).\n\nThe aim of the study is to identify genetic susceptibility to Listeriosis.",[274],"Listeriosis","2025-09-18",{"date":277,"type":31},"2025-09-19",{"date":279,"type":31},"2017-11-28",{"date":281,"type":22},"2027-11-30",{"name":37,"class":38},{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":93,"sex":18,"minAge":290,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":294,"conditions":295,"keywords":297,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":84},"100303102","simian-foamy-virus-transmission-to-humans-100303102","NCT03225794","Simian Foamy Virus Transmission to Humans","Epidemiological and Molecular Aspects of the Interspecies Transmission of Foamy Viruses From Monkeys to Humans: A Model of the Early Stages of Viral Emergence.","Inclusion Criteria:\n\n* Living in a rural zone of Cameroon\n* Being \\> 5 yrs old\n* Having received study information and having provided written consent for self and children, if applicable (for all phases)\n\nExclusion Criteria:\n\n* Having refused to provide consent\n* Being less than 5 years old","5 Years","90 Years",{"count":293,"type":22},1600,"About three quarters of the viral agents that have emerged recently in humans are considered to originate from other animals. These viruses have often evolved and spread into the human population through various mechanisms after the initial contact that resulted in interspecies transmission. However, knowledge of the initial stages of the emergence of viruses and associated diseases is still limited in many cases. Microbiological monitoring in populations at risk of transmission would provide insights into the initiation and early stages of the emergence process.\n\nNonhuman primates (NHPs) share many genetic, physiological, and microbiological features with humans, and are potential sources of many infectious agents. This has been demonstrated for several simian retroviruses. HIV-1 and 2 are believed to have originated from chimpanzee and mangabey viruses, respectively, found in Central and West Africa. The current distribution of the various molecular subtypes of the HTLV-1 oncogenic retrovirus in Africa is mainly the result of numerous instances of interspecies transmission of STLV-1from NHP species in the distant past.\n\nFoamy viruses belong to the Retrovidae family and the Spumavirus genus. They are complex exogenous retroviruses and are very common in many animal species, including primates, cats, cattle, and horses, in which they cause persistent infections.\n\nThe first aim of the work is to study the epidemiological and molecular aspects of the transmission of foamy viruses from monkeys to humans in populations at risk, such as the inhabitants (especially hunters) in the villages of the dense forests of southern Cameroon. It is an area in which NHPs are still very common, with a great diversity of species. The investigators have already shown that the prevalence of foamy viruses is very high in these monkeys and great apes (gorillas and chimpanzees). Contact between these monkeys and the villagers is very frequent, mainly during hunting. The second aim of the project is to study the clinical and biological features of infected people and investigate intrafamilial transmission from infected index cases.",[296],"Simian Foamy Virus Infection (Disorder)",[298,299],"Retrovirus","Viral emergence",{"date":301,"type":31},"2025-09-22",{"date":303,"type":31},"2010-11-01",{"date":305,"type":22},"2027-12-31",{"name":37,"class":38},{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":315,"enrollmentInfo":316,"targetDuration":4,"studyType":98,"phases":318,"briefSummary":320,"conditions":321,"keywords":323,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":334},"100502378","phase-3-efficacy-of-an-adapted-antibiotherapy-in-hurley-stage-2-hidradenitis-suppurativa-patients-100502378","NCT05821478","Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients","A Multicentric Randomized Double-Blind Phase 3 Trial Evaluating the Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Active Hidradenitis Suppurativa Patients Versus Tetracycline Derivative","ABCESS2","Inclusion Criteria:\n\n* Adults \\\u003C 60 years old\n* Diagnosis of HS according to European Dermatology guidelines:\n\n  * Recurrent inflammation occurring more than 2 times in the past 6 months in the inverse regions of the body, presenting with nodules, sinus-tracts and\u002For scarring.\n  * Signs: Involvement of axilla, genitofemoral area, perineum, gluteal area (and infra-mammary areafor women). Presence of nodules (inflamed or noninflamed), sinus tracts (inflamed or noninflamed), abscesses, scarring (atrophic, mesh-like, red, hypertrophic or linear)\n* Active HS with i) ≥ 1 year of evolution and ii) ≥ 4 flares during the previous year\n* Clinical severity of HS at inclusion: Hurley stage 2\n* BMI \\\u003C 35\n* Written informed consent from patient\n* Patient able to complete DLQI\n* Patients affiliated to the French health system (Assurance Maladie), except French state medical aid beneficiaries (Aide Médicale d'Etat)\n* Active compatible contraception for men and women of childbearing or inability to procreate\n* Available laboratory blood test performed within the last 2-months\n\nNon inclusion Criteria:\n\n* Person \\\u003C 18 and ≥ 60 years old\n* Former stage 3 HS\n* Previous use of the experimental treatment\n* Unauthorized drugs for the study during the month preceding the inclusion\n* Any contra-indication to study treatments or excipient (e.g. lactose, cornstarch, riboflavin notably):\n\npregnancy, breastfeeding, known allergy to experimental or reference drugs, wheat allergy, tendinopathy, QT prolongation, bradycardia, heart failure, heart rhythm disturbances, hydroelectrolytic disorders, hypokalemia, coagulation disorders, severe liver\u002Fkidney dysfunction, porphyria, mandatory use of nonsteroidal anti-inflammatory drugs (NSAIDs) for other medical conditions\n\n* Unbalanced diabetes (ie HbA1c above 7%)\n* Dysphagia, untreated gastro-oesophageal reflux\u002Fulcer\n* BMI ≥ 35\n* Immune suppression, inflammatory disease, including gastroenterologic and rheumatologic inflammatory conditions\n* Lactase deficiency, lactose and galactose intolerance\n* Malabsorption syndrome\n* Person living in the same household as another patient\n* Person under guardianship or curatorship\n* Individuals with any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives (e.g patient unable to complete DLQI, or poor predictable observance\n* Participation in another interventional research on health products studies\n* Patients requiring repeated (more than 3\u002Fyear) use of antibiotics for a chronic disease other than HS\n* Alcohol-dependant patients defined as an addiction to alcohol with a negative impact on health, social or personal life\n\nExclusion criteria:\n\nPregnancy QT prolongation Abnormal result of routine lab tests corresponding to contra-indication to study treatments Unauthorized drug for the study during all the study (from study treatments interactions listed in the SmPC, Cf. unauthorized drug listed in non-inclusion criteria).\n\nDevelopment of hypersensitivity to any of the study products and\u002For excipients (e.g. lactose, corn starch, riboflavin).","59 Years",{"count":317,"type":22},92,[319],"PHASE3","The study evaluates the efficacy of an adapted antibiotherapy in Hurley stage 2 active Hidradenitis Suppurativa patients versus tetracycline derivative",[322],"Hidradenitis Suppurativa",[322,324,325],"Antibioresistance","Antibiotherapy","2025-07-03",{"date":328,"type":31},"2025-07-09",{"date":330,"type":31},"2025-05-22",{"date":332,"type":22},"2028-02-27",{"name":37,"class":38},4,{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":93,"sex":18,"minAge":19,"maxAge":342,"enrollmentInfo":343,"targetDuration":4,"studyType":98,"phases":345,"briefSummary":346,"conditions":347,"keywords":350,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":84},"100571275","description-of-the-immune-response-to-yellow-fever-vaccination-100571275","NCT06718127","Description of the Immune Response to Yellow Fever Vaccination","IVORY2","Inclusion Criteria:\n\n* Age between 18 and 65\n* Referred for immunisation against yellow fever and typhoid\n* Any person with indication for the following vaccinations :\n* Yellow fever\n* Typhoïd\n* Whose vaccination schedule includes two appointments 7 days apart\n* Whose state of health is compatible with a single 51 ml blood sample collection\n* Have consented to participate in the Ivory2 study\n* Benefiting from a Social Security plan or equivalent\n\nExclusion Criteria:\n\n* Anyone with a contraindication to yellow fever and\u002For typhoid vaccination.\n* Any person who has been vaccinated against yellow fever and\u002For typhoid.\n* Anyone who has lived in an endemic area (≥ 1 year) and\u002For has a history of Typhoid.\n* Anyone who is unable to attend the visit 1-month after the typhoid vaccine injection.\n* Women claiming to be pregnant or breast-feeding\n* Anyone unable to give informed consent for participation","65 Years",{"count":344,"type":22},38,[100],"Vaccine protection depends on a specific adaptive immune memory. However, a little-explored aspect of certain live vaccines may provide beneficial, non-specific protection against infections or pathogens other than the one from which the vaccine is derived. This is the concept of innate immune memory or \" trained immunity\", which differs from adaptive memory in its non-specificity. Innate immune memory is triggered by exposure to immunostimulants, and offers protection against unrelated pathogenic threats for several months or even years.\n\nThe project aims to carry out an exploratory study to observe, in the context of current practice, the immune response obtained after a subunit and a live attenuated vaccine",[348,349],"Immunization","Infections",[351,352],"immunology","Vaccine response","2025-06-27",{"date":355,"type":31},"2025-06-29",{"date":357,"type":31},"2024-09-30",{"date":359,"type":22},"2027-04-30",{"name":37,"class":38},{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":98,"phases":370,"briefSummary":371,"conditions":372,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":379,"locationsCount":380},"100550797","cellular-and-molecular-biomarkers-in-patients-with-lichen-planus-100550797","NCT06451744","Cellular and Molecular Biomarkers in Patients With Lichen Planus","Evaluation of the Clinical Specificity of Cellular and Molecular Biomarkers Identified in Patients With Lichen Planus","HELP","Inclusion Criteria:\n\n* Subject coming at the time of diagnosis of the disease before any systemic treatment, or at the time of a progressive episode of the disease, without systemic treatment or after cessation of immunomodulatory or immunosuppressive treatment\n* Ability to give their consent in writing\n* Must understand spoken and written French\n* Affiliated to the French social security or assimilated regimes\n\nExclusion Criteria:\n\n* Dermatosis exclusively localised in the skin folds or on the face (risk of scarring from biopsies)",{"count":47,"type":22},[100],"Lichen planus (LP) is a chronic inflammatory disease of unknown aetiology, affecting the skin and mucous membranes, characterised by a CD8+ cytotoxic T-cell infiltrate, associated with epithelial cell death and disruption of the basement membrane zone. In previous work, T cell antigen receptor (TCR) repertoire studies were performed. In all patients tested, whether with erosive or non-erosive LP, unique nucleotide sequences, called clonotypes, have been identified. They appear during the process of TCR gene rearrangement. These clonotypes are specific for human papillomavirus (HPV) in blood and lesions, suggesting antigenic stimulation of these clonotypes by a viral epitope of HPV, which crosses with an epitope on keratinocytes. The diagnosis of LP is made on the basis of clinical and histological criteria, but in some patients and in some anatomical locations, the diagnosis is difficult to make and LP may be confused with other skin conditions.",[373],"Lichen Planus",{"date":375,"type":31},"2025-07-01",{"date":377,"type":31},"2023-11-01",{"date":359,"type":22},{"name":37,"class":38},6,{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":385,"acronym":386,"eligibilityCriteria":387,"healthyVolunteers":93,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":98,"phases":390,"briefSummary":391,"conditions":392,"keywords":396,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":72},"100504902","circulating-biomarker-signatures-for-the-detection-of-gastric-preneoplasia-and-cancer-100504902","NCT05854368","Circulating Biomarker Signatures for the Detection of Gastric Preneoplasia and Cancer","PREGASIGN#1","Inclusion Criteria:\n\nCommon\n\n* 18 years old or highter\n* written informed consent prior to any study procedure\n* Affiliated to a social insurance system\n\nSpecific to patients with gastric lesions\n\n* Untreated glandular atrophy (with or without intestinal metaplasia and\u002For dysplasia) and histologically diagnosed as of 2014\n* Treatment naïve Gastric cancer (distal or proximal adenocarcinoma)\n\nExclusion Criteria:\n\nCommon\n\n* Autoimmune disease or disease that impacts the immune system (e.g: HIV)\n* Chronic inflammatory disease\n* Known evolutive cancer (excluding gastric cancer)\n* Treated in the last 3 months or currently treated with therapy that interferes with the immune system (e.g. immunosuppressive therapy)\n* Current treatment with long-term corticosteroid therapy\n* Current treatment with long-term nonsteroidal anti-inflammatory drugs\n* Pregnant woman or breastfeeding\n* Patient or healthy volunteer under legal protection (e.g. guardianship)\n* Patient or healthy volunteer currently participating to a clinical trial evaluating either an experimental medical product or a medical device\n* Patient or healthy volunteer currently in custody\n\nSpecific to Healthy Volunteer\n\n* Known history of Helicobacter pylori infection\n* Known history of gastric lesions (i.e. chronic gastritis, gastric atrophy, intestinal metaplasia, dysplasia and cancer)",{"count":389,"type":22},2500,[100],"The goal of this study is to characterize and validate a signature of circulating biomarkers in plasma, associated with the presence of gastric preneoplasia in patients with preexisting gastric lesion compared with a control group.\n\nFor this purpose:\n\n* Patients with pre-existing gastric lesions will be invited to participate to this study. If they are willing to participate an additional blood sample (9 mL) will be collected at the time of the blood collection performed during their routine care\n* Healthy subjects will be invited to participate to constitute the control group. If they are willing to participate a blood sample (9 ml) will be drawn specifically for this study",[393,394,395],"Gastric Lesion","Gastric Precancerous Condition","Gastric Cancer",[397],"Gastric Cancer, biomarkers,","2025-05-13",{"date":400,"type":31},"2025-05-16",{"date":402,"type":31},"2023-07-03",{"date":404,"type":22},"2025-12",{"name":37,"class":38},{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":415,"conditions":416,"keywords":418,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":84},"100447805","exploration-of-the-cellular-and-molecular-mechanisms-in-patients-receiving-biotherapies-targeting-the-il-23il-17-axis-in-cutaneous-psoriasis-100447805","NCT05111210","Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23\u002FIL-17 Axis in Cutaneous Psoriasis","Pso23","Inclusion Criteria:\n\nAll patients:\n\n* Adults (\\>18 years)\n* Presenting with cutaneous psoriasis\n* Patients have signed an informed consent\n* Beneficiary of the health insurance, except for the AME Only for patients of Group 1\n* Patients require systemic treatment for psoriasis\n* Patients are naïve to biological therapies\n\nOnly for patients of Group 2:\n\n* Patients requiring treatment with anti-IL-23 biologics (guselkumab, risankizumab, tildrakizumab) upon referent physician's decision.\n* Patients are naïve to biological therapies or have received only one biologic, with a \"wash-out\" period of at least 4 months\n\nNon inclusion Criteria:\n\nFor all :\n\n* Patient is minor\n* Patient is pregnant or breastfeeding\n* Patient is immunocompromised\n* Patient is under legal protection, curatorship, guardianship\n* Patient refuses consent\n* Patient is unable to comply with study requirements for geographic, social or psychiatric reason.\n* Beneficiary of the AME Only for patients of Group 1\n* Patient has received biologics Only for patients of Group 2\n* Patient has a contraindication to the chosen biotherapy\n* Patient has received biologics within the last 4 months\n* Patient has been treated with 2 or more biologics\n* Patient has already received an anti-IL-23 biologic",{"count":414,"type":22},90,"This is a research study involving humans, of the interventional type with minimal risks and constraints (RIPH2). It is a monocentric, non randomized prospective study aiming to better understand the mechanisms of the response to anti-IL-23 biologics in psoriasis patients attending the dermatology department of hospital Cochin (APHP).",[417],"Psoriasis",[419,420,421],"psoriasis","anti-IL-23 therapy","immune responses",{"date":423,"type":31},"2025-05-14",{"date":425,"type":31},"2021-12-14",{"date":427,"type":22},"2028-06-30",{"name":37,"class":38},{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":433,"acronym":434,"eligibilityCriteria":435,"healthyVolunteers":93,"sex":18,"minAge":19,"maxAge":342,"enrollmentInfo":436,"targetDuration":4,"studyType":98,"phases":437,"briefSummary":438,"conditions":439,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":84},"100505219","understanding-the-determinants-of-mucosal-immunity-and-optimizing-the-diagnosis-of-infection-with-sars-cov-2-variants-100505219","NCT05858502","Understanding the Determinants of Mucosal Immunity and Optimizing the Diagnosis of Infection With SARS-CoV-2 Variants","COVARIANT","Inclusion Criteria:\n\n* Common criteria for all subjects:\n\n  * Aged between 18 and 65 years included\n  * Whose weight is greater than or equal to 50 kg and whose state of health is compatible with the collection of 55 ml of blood at one time and 111 ml in 28 days\n  * Residing in the Ile-de-France region and able to travel to the 15th arrondissement of Paris for visits to ICAReB-Clin\n  * Having given their consent to participate in the study\n  * Benefiting from a Social Security scheme except for the Aide Médicale d'Etat\n* Criteria for the SARS-CoV-2 infected participant group:\n\n  * Subject tested positive for SARS-CoV-2 by RT-PCR in one of the participating laboratories for less than 72 hours\n  * Asymptomatic or with symptoms not requiring hospitalization regardless of previous vaccination or infection status for SARS-CoV-2.\n* Criteria for the SARS-CoV-2 uninfected group:\n\n  * Having tested negative for SARS-CoV-2 by RT-PCR\n  * Subject with no more than 3 co-morbidities listed by the HAS.\n\nExclusion Criteria:\n\n* Criteria common to all subjects :\n\n  * Subject under a protective measure (e.g., guardianship)\n  * Participant in another biomedical research\n  * For women: pregnant or breastfeeding women (declarative)\n  * Subject with another acute infectious disease\n  * SARS-CoV-2 RT-PCR result older than 3 days\n  * Existence of at least 3 co-morbidities known to be factors of severity (and therefore representing risks of hospitalisation during follow-up)\n  * Existence of a previous known SARS-CoV-2 positivity less than 1 month old (whatever the method used: RT-PCR or antigenic test)\n* SARS-CoV-2 infected participant group criteria:\n\n  \\- For symptomatic subjects: onset of symptoms more than 4 days ago\n* SARS-CoV-2 uninfected participant group criteria:\n\n  * Known history of infection and\u002For COVID-19 vaccination, within the previous 3 months",{"count":414,"type":22},[100],"One of the current health challenges in the face of the COVID-19 pandemic that started in Wuhan in 2019, and still responsible for successive waves, is to better understand and diagnose the infection.\n\nThe new variants - delta, then omicron, which appeared in November 2021 and then their sub-variants BA.2, then BA.4 and 5, and more recently BQ.1 and the sub-variant XBB.1.5 are increasingly transmissible and responsible for some degree of immune escape. Hence the importance of a better understanding of infection- or vaccine-induced immunity in order to optimize existing prophylactic or therapeutic strategies, or even to develop new, more effective ones.\n\nMucosal immunity could play a particularly important role in interrupting the infection cycle at the entry point of the virus.\n\nThe key role of innate immunity has been demonstrated in particular, via interferons and the composition of the microbiota.\n\nHumoral immunity is the best documented. However, it tends to be eroded within a few months. On the other hand, cellular immunity is more stable over time and would largely explain the decrease in severe forms of the disease in vaccinated individuals.\n\nThe collection of biological resources that will be built up during this study will also allow us to optimize or develop new diagnostic methods, necessary as a complement to vaccination, to effectively slow down the spread of the pandemic and reduce the severity of its impact on the population.\n\nThe improvement of diagnostic methods will in turn improve the understanding of the infection by providing increasingly reliable information on the characteristics of an infection, its quantification, its dynamics, and its resolution, especially since these parameters will be compared, at any time during the study, with reference methods and the immunological status of the subject.\n\nThe main significant improvements expected in the field of SARS-CoV-2 diagnosis are notably the improvement of performance (reduction of false negatives in RT-PCR on nasopharyngeal samples), acceptability, simplicity of implementation in the field, and the capacity to test transmission.\n\nThe objective of this study is to identify and characterize SARS-CoV-2 infection and host response, particularly mucosal immunity.",[440],"COVID-19","2025-05-12",{"date":423,"type":31},{"date":444,"type":31},"2023-12-15",{"date":446,"type":22},"2026-06-18",{"name":37,"class":38},{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":452,"acronym":453,"eligibilityCriteria":454,"healthyVolunteers":93,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":455,"targetDuration":4,"studyType":98,"phases":457,"briefSummary":458,"conditions":459,"keywords":461,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":84},"100570026","observational-study-of-travellers-pathologies-100570026","NCT06701890","Observational Study of Travellers Pathologies","EOP","1. Inclusion Criteria :\n\n   1. For all participants in the EOP study :\n\n      * Major subject (age ≥ 18)\n      * Owns a smartphone compatible with electronic data collection\n      * Preparing to travel outside mainland France\n      * Affiliated with or covered by Social Security or private insurance\n      * Willing to participate in the EOP study\n   2. For the EOP-Arbo Sub-study :\n\n      \\- Subject who has consented to participate in the EOP\\_Arbo study.\n   3. For the EOP-AMR Sub-study :\n\n      * Subject who has consented to participate in the EOP\\_AMR study.\n2. Exclusion Criteria:\n\n   1. For all participants in the EOP study :\n\n      * Travel duration ≤ 3 days\n      * Travel duration \\> 12 months\n      * Person traveling as part of an expatriation without planned movement outside the settlement in the destination country\n      * Person under legal protection or unable to express consent for participation\n   2. For the EOP-Arbo Sub-study :\n\n      \\- Individuals deemed clinically and\u002For biologically unfit by the investigator to undergo the blood samples required for the study.\n   3. For the EOP-AMR Sub-study :\n\n      * No specific exclusion criteria.",{"count":456,"type":22},11000,[100],"Traveling to emerging countries is associated with a significant risk of encountering health issues specific to the destination, such as gastrointestinal and respiratory infections, malaria episodes, and road traffic accidents.These conditions are associated with behavioral, geographical, or environmental risk factors. A better understanding of these factors will enable the development of targeted recommendations to minimize travel related health issues.\n\nThe main objective of this study is to determine the incidence of pathologies occurring during travel outside the metropolitan territory.",[460],"Travel-Related Illness",[462,463,464,465],"Travel","Risk Factors","Pathology","Arbovirose","2025-04-30",{"date":468,"type":31},"2025-05-01",{"date":470,"type":31},"2024-12-09",{"date":472,"type":22},"2036-12",{"name":37,"class":38},{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":478,"acronym":479,"eligibilityCriteria":480,"healthyVolunteers":93,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":98,"phases":483,"briefSummary":484,"conditions":485,"keywords":486,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":495,"locationsCount":4},"100588778","characterizing-the-host-response-to-leptospirosis-for-better-diagnosis-and-prognosis---nihfi-100588778","NCT06945822","Characterizing the Host Response to Leptospirosis for Better Diagnosis and Prognosis - NIHFI","NIHFI","Inclusion Criteria:\n\nFor all participants :\n\n* Be able to consent,\n* Have received information and given written consent,\n* Be covered by a social security plan. For groups 1 \\& 2: febrile individuals\n* Have suspected leptospirosis associated with fever (axillary temperature over 38°C) and a clinical picture of suspected leptospirosis (myalgia, headache...). After inclusion, febrile participants will be divided into 2 groups when the diagnosis of leptospirosis is confirmed. The 2 groups are defined as follows:\n\nGroup 1: leptospirosis\n\n\\- Individual with leptospirosis confirmed by PCR, MAT, or isolation (2013 Center For Disease Control and Prevention (CDC) laboratory criteria for a confirmed diagnosis).\n\nGroup 2: MFA, with absence of leptospirosis\n\nAll individuals in Group 2 will have tests as part of their MFA diagnosis, depending on their symptomatology:\n\n* Other acute bacterial zoonotic infection: Infection confirmed by paired serology or double PCR (2 targets).\n* Acute arboviral infection: dengue, chikungunya or Zika virus confirmed by CDC Trioplex PCR in a patient with consistent serology or positive 2nd target PCR.\n* Acute respiratory viral infection: Viral agent confirmed by MFA multiplex PCR. For group 3: healthy individuals\n* Apyretic individuals, no symptoms of infection or inflammatory disease in the last 28 days.\n\nExclusion Criteria:\n\nindividuals :\n\n* with a chronic inflammatory disease,\n* undergoing concomitant antibiotic and\u002For anti-inflammatory treatment, or under medical care incompatible with the purpose of the study,\n* pregnant or breast-feeding women,\n* persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care and persons admitted to a health or social institution,\n* Adults subject to a legal protection measure or unable to express their consent\n* Persons not affiliated to a social security scheme or beneficiaries of such a scheme\n* Hospitalized for more than 48 hours,\n* Hospitalized or operated on in the previous 7 days.",{"count":482,"type":22},450,[100],"Leptospirosis is a zoonosis found worldwide, but particularly in humid subtropical and tropical zones. It is caused by pathogenic bacteria of the Leptospira species of the spirochete family. It is estimated that there are over a million cases of leptospirosis worldwide each year, with 60,000 deaths. These figures place leptospirosis among the most dangerous bacterial zoonoses in the world.\n\nThe disease affects the most disadvantaged populations, and also inflicts its burden on domestic and farm animals. To this day, however, leptospirosis remains a neglected disease, poorly understood because it has been little studied.\n\nHuman leptospirosis initially presents as a febrile syndrome, with fever, headache, myalgia and joint pain. These symptoms are very similar to those observed in influenza, dengue fever and other acute febrile illnesses, making diagnosis very difficult.\n\nDelayed initiation of antibiotic therapy, a treatment recommended by the WHO, is associated with the development of severe forms of leptospirosis. Indeed, in 10% of cases, leptospirosis evolves into severe forms, which are still poorly described, but which result in haemorrhage, multivisceral failure (lungs, kidneys, liver) and a drastic increase in the case-fatality rate. In 2023, 152 cases of leptospirosis were reported in New Caledonia. Of these, 130 people (85%) were hospitalized and 4 deaths were recorded (2.6%).\n\nFor patients suffering from leptospirosis, it is therefore important to be able to make the diagnosis quickly, ideally as soon as symptoms appear. It is also crucial to be able to monitor, or even prevent, the development of severe forms of the disease, to ensure optimal patient care.",[50],[487,126,488],"biomarkers","infection","2025-04-18",{"date":491,"type":31},"2025-04-25",{"date":493,"type":22},"2025-06-01",{"date":61,"type":22},{"name":37,"class":38},{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":93,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":98,"phases":506,"briefSummary":507,"conditions":508,"keywords":510,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":4},"100588386","exploring-the-links-between-hearing-cognition-and-brain-activity-in-people-with-tinnitus-100588386","NCT06940726","Exploring the Links Between Hearing, Cognition and Brain Activity in People With Tinnitus","Exploration Des Liens Entre Audition, Cognition et activité cérébrale Chez Des Personnes présentant un acouphène","GHOSTTONE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Good written and oral comprehension of the French language\n* Normal or corrected vision\n\nGroup of people with tinnitus :\n\n\\- Chronic tinnitus \\> 3 months, uni or bilateral, stable (no period of remission)\n\nControl group :\n\n\\- No tinnitus\n\nExclusion Criteria:\n\n* Presence of a known neurological disorder\n* Presence of a known degenerative pathology\n* Presence of a known hearing impairment\n* Presence of a motor disability of the upper limbs\n* Severe or profound deafness on one or both sides\n* Person under legal protection (guardianship, curatorship, etc.)\n* Use of hearing aids",{"count":505,"type":22},114,[100],"The goal of this observational study is to understand the mechanisms underlying tinnitus, and improve the clinical assessment strategies needed to develop targeted therapeutic interventions by comparing endogenous attention capacities in healthy subjects and subjects with tinnitus",[509],"Tinnitus",[511],"tinnitus","2025-04-15",{"date":514,"type":31},"2025-04-23",{"date":516,"type":22},"2025-05",{"date":518,"type":22},"2027-11",{"name":37,"class":38},{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":93,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":528,"targetDuration":4,"studyType":98,"phases":530,"briefSummary":531,"conditions":532,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":542},"100586884","study-of-auditory-perception-after-progressive-exposure-to-aversive-sounds-in-people-with-misophonia-100586884","NCT06921187","Study of Auditory Perception After Progressive Exposure to Aversive Sounds in People With Misophonia","Etude de la Perception Auditive après Exposition PROgressive Aux Sons Aversifs Chez Des Personnes MISophonEs","PROMISE","Inclusion Criteria:\n\nFor all participants\n\n* Obtain oral consent from the participant after receiving information about the study,\n* Be 18 years or older on the day of inclusion,\n* Be fluent in French (spoken and written),\n* Have no known hearing loss, verified by pure tone audiometry.\n* Declare that they do not have tinnitus,\n* Declare that they do not have hyperacusis, verified by measuring discomfort thresholds.\n* Be affiliated to the social security or equivalent scheme.\n\nFor participants with misophonia:\n\n\\- Declare discomfort, reduced tolerance to specific sounds (mouth noises, throat clearing, breathing, etc.).\n\nExclusion Criteria:\n\n* Bear the after-effects of an ear infection and\u002For have a history of an ENT disease that permanently affects hearing or balance (vestibular schwannoma, Ménière's disease, sudden or fluctuating deafness, congenital hypoacusis),\n* Be under guardianship,\n* deprived of liberty by judicial or administrative decision, or subject to legal protection.",{"count":529,"type":22},110,[100],"The primary objective of the project is to characterise and measure the auditory perception of subjects with misophonia compared with the auditory perception of control subjects.",[533],"Misophonia","2025-04-03",{"date":536,"type":31},"2025-04-10",{"date":538,"type":22},"2025-06",{"date":540,"type":22},"2026-03",{"name":37,"class":38},2,{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":547,"acronym":548,"eligibilityCriteria":549,"healthyVolunteers":93,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":550,"targetDuration":4,"studyType":98,"phases":552,"briefSummary":553,"conditions":554,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":84},"100548432","measuring-and-restoring-auditory-awareness-for-cochlear-implant-listeners-in-noise-100548432","NCT06420921","MeasurIng and Restoring Auditory Awareness for Cochlear Implant Listeners in noisE","MIRACLE","Inclusion Criteria:\n\nFor all participants:\n\n* 18 years of age or over,\n* Native French speaker,\n* Having given their consent to take part in the research.\n\nFor cochlear implant patients:\n\n* Adult implanted and declaring that they have been using the implant for at least 18 months,\n* Normal speech audiometry in silence\n\nFor controls reporting normal hearing:\n\n* Normal tonal audiometry (defined as a mean tonal loss not exceeding 30 decibel (dB) HL)\n* Normal speech audiometry in noise (SNR between -8 dB and -4dB inclusive)\n\nExclusion Criteria:\n\n* Be under guardianship or curatorship,\n* deprived of liberty by judicial or administrative decision, or subject to legal protection,\n* Non- native French speaker.",{"count":551,"type":22},50,[100],"The goal of this interventional study is to describe how people with cochlear implants perceive the perceive speech in noise and their sound environment on adults who are native French speakers with typical hearing or with cochlear implant(s).\n\nThe measures and strategies developed in this project could benefit all current and future cochlear implant wearers by improving their perception of the sound environment and their quality of life on a daily basis.\n\nResearchers will compare normal hearing participant and participants with cochlear implant to describe the speech in noise and their perception of the sound environment.\n\nParticipants will perform audiological tests to assess their perception of the sound environment, with and without speech enhancement.",[555],"Cochlear Hearing Loss","2025-02-28",{"date":558,"type":31},"2025-03-03",{"date":560,"type":22},"2025-03",{"date":562,"type":22},"2026-10",{"name":37,"class":38},{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":568,"acronym":569,"eligibilityCriteria":570,"healthyVolunteers":93,"sex":18,"minAge":571,"maxAge":572,"enrollmentInfo":573,"targetDuration":4,"studyType":98,"phases":575,"briefSummary":576,"conditions":577,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":579,"startDateStruct":580,"completionDateStruct":581,"leadSponsor":583,"locationsCount":4},"100537781","elicitation-of-steady-state-audiovisual-responses-in-6--and-10-month-old-infants-100537781","NCT06282289","Elicitation of Steady-state Audiovisual Responses in 6- and 10-month-old Infants","AV-SSR-I","Inclusion Criteria:\n\n* be 6 or 10 months old (+\u002F- 2 weeks)\n* have received age-appropriate information on the experiment\n* their legal guardians have received appropriate information and given their oral consent.\n\nExclusion Criteria:\n\n* A neurological disorder (visual, auditory, motor, executive)\n* Developmental delay","6 Months","10 Months",{"count":574,"type":22},64,[100],"The goal of this study is to investigate the preferential responses of speech neural systems in infants.\n\nThe main question it aims to answer is to determine whether the oscillatory synchronization capacity is associated with children's language level (i.e. vocabulary).\n\nParticipants will be presented with synthetically modulated stimuli at three frequency scales: 4 Hz, 5 Hz and 30 Hz.",[578],"Speech",{"date":558,"type":31},{"date":516,"type":22},{"date":582,"type":22},"2025-09-21",{"name":37,"class":38},{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":588,"acronym":589,"eligibilityCriteria":590,"healthyVolunteers":93,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":593,"conditions":594,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":595,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":542},"100536393","users-of-remote-conferencing-and-compression-of-sound-dynamics--auditory-effects-100536393","NCT06264245","Users of Remote Conferencing and Compression of Sound Dynamics : Auditory Effects","COMPRESSED","Inclusion Criteria:\n\nFor all participants:\n\n* Age 18 or over,\n* Work with platforms using sound signal processing systems,\n* Fluent in English,\n* Fluent in French,\n* Declare that they have no hearing loss.\n\nFor participants in the high exposure group:\n\n\\- Have had a professional activity over the last three years using broadcasting platforms with sound signal processing systems,\n\nFor participants in the moderate or limited exposure group:\n\n\\- Have worked between one semester and two years with platforms using sound signal processing systems.\n\nExclusion Criteria:\n\n* Conductive or mixed hearing loss, i.e. where the hearing loss affects both the outer and\u002For middle ear and the inner ear.\n* Have an asymmetric hearing loss, i.e. a difference in average hearing loss between the left and right ear of more than 20 dB,\n* Have a history of otitis and\u002For an ENT disease that permanently affects hearing (vestibular schwannoma, Ménière's disease, sudden or fluctuating deafness, congenital hypoacusis),\n* Not fluent in English\n* Be under guardianship,\n* Deprived of liberty by judicial or administrative decision, or subject to legal protection.",{"count":592,"type":22},200,"The COMPRESSED project is a descriptive, bi-centric and non-invasive study carried out by the CERIAH - IDA - Institut Pasteur and the Haute École Léonard de Vinci in Brussels on volunteer participants identified in two groups :\n\n* be subject to high exposure to compressed sound, as defined by professional participation in events on broadcast platforms using sound signal processing systems, over the last 3 years,\n* be subject to moderate or limited exposure to compressed and manipulated sound, equivalent to that of a student following certain distance learning courses. on a videoconferencing platform, alternating with other face-to-face courses, with the ability to listen during breaks, which have been taught for a maximum of 2 years.\n\nThe main objective of the COMPRESSED study is to evaluate the auditory effects of exposure to manipulated sounds (compression, filtering, equalisation, accentuation, etc.) from sound distribution platforms on the auditory system of participants who are regularly exposed to these sounds as a result of their professional activity.",[103],{"date":558,"type":31},{"date":597,"type":31},"2024-06-01",{"date":599,"type":22},"2026-01-15",{"name":37,"class":38},""]